

Regional differences and coronary microvascular dysfunction in heart failure with preserved ejection fraction

Mikael Erhardsson^{1*}, Ulrika Ljung Faxén^{1,2}, Ashwin Venkateshvaran¹, Sara Svedlund³, Antti Saraste⁴, Maria Lagerström Fermer⁵, Li-Ming Gan^{6,7}, Sanjiv J. Shah⁸, Jasper Tromp^{9,10,11}, Carolyn SP Lam^{11,12}, Lars H. Lund^{1,13} and Camilla Hage^{1,13}

¹Department of Medicine, Cardiology Unit, Karolinska Institutet, Stockholm, Sweden; ²Karolinska University Hospital, Perioperative Medicine and Intensive Care, Stockholm, Sweden; ³Department of Clinical Physiology, Institute of Medicine, Sahlgrenska University Hospital, University of Gothenburg, Gothenburg, Sweden; ⁴Heart Center, Turku University Hospital, University of Turku, Turku, Finland; ⁵Early Clinical Development, IMED Biotech Unit, AstraZeneca Gothenburg, Sweden; ⁶Ribocure Pharmaceuticals AB, Sweden, Suzhou Ribo Life Science Co. Ltd., China; ⁷Department of Cardiology, Department of Molecular and Clinical Medicine, Institute of Medicine, Sahlgrenska Academy at the University of Gothenburg, Gothenburg, Sweden; ⁸Division of Cardiology, Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL, USA; ⁹Saw Swee Hock School of Public Health, National University of Singapore & the National University Health System, Singapore, Singapore; ¹⁰Duke-NUS Medical School, Singapore, Singapore; ¹¹National Heart Centre Singapore, Duke-National University of Singapore, Singapore, Singapore; ¹²University Medical Centre Groningen, Groningen, the Netherlands; and ¹³Karolinska University Hospital, Heart and Vascular Theme, Stockholm, Sweden

Abstract

Aims In heart failure with preserved ejection fraction (HFpEF), regional heterogeneity of clinical phenotypes is increasingly recognized, with coronary microvascular dysfunction (CMD) potentially being a common shared feature. We sought to determine the regional differences in clinical characteristics and prevalence of CMD in HFpEF.

Methods and results We analysed clinical characteristics and CMD in 202 patients with stable HFpEF (left ventricular ejection fraction $\geq 40\%$) in Finland, Singapore, Sweden, and United States in the multicentre PROMIS-HFpEF study. Patients with unvascularized macrovascular coronary artery disease were excluded. CMD was assessed using Doppler echocardiography and defined as coronary flow reserve (adenosine-induced vs. resting flow) < 2.5 . Patients from Singapore had the lowest body mass index yet highest prevalence of hypertension, dyslipidaemia, and diabetes; patients from Finland and Sweden were oldest, with the most atrial fibrillation, chronic kidney disease, and high smoking rates; and those from United States were youngest and most obese. The prevalence of CMD was 88% in Finland, 80% in Singapore, 77% in Sweden, and 59% in the United States; however, non-significant after adjustment for age, sex, N-terminal pro-brain natriuretic peptide, smoking, left atrial reservoir strain, and atrial fibrillation. Associations between CMD and clinical characteristics did not differ based on region (interaction analysis).

Conclusions Despite regional differences in clinical characteristics, CMD was present in the majority of patients with HFpEF across different regions of the world with the lowest prevalence in the United States. This difference was explained by differences in patient characteristics. CMD could be a common therapeutic target across regions.

Keywords Coronary flow reserve; Coronary microvascular dysfunction; HFpEF; Region

Received: 15 January 2023; Revised: 5 September 2023; Accepted: 2 October 2023

*Correspondence to: Mikael Erhardsson, Department of Medicine, Cardiology unit, Karolinska Institutet, SE-171 76 Stockholm, Sweden. Email: mikael.erhardsson@ki.se

Introduction

Heart failure (HF) with preserved ejection fraction (HFpEF) is associated with multiple common co-morbidities suggested to drive systemic inflammation and endothelial dysfunction,

leading to coronary microvascular dysfunction (CMD).¹ CMD is present in 75% of patients with HFpEF and associated with an increased risk of HF hospitalization and mortality.^{2,3} Even though a single treatment strategy to reduce mortality and morbidity in HFpEF exists in sodium glucose co-transporter-2

(SGLT-2) inhibitors,^{4,5} the effectiveness may differ in different phenotypes due to disease heterogeneity. Exploration and subgroup characterization may reveal phenotype-specific treatment targets.⁶

While geographical influences on HFpEF phenotypes have been previously suggested, regional differences in CMD have not been explored. Data from the PARAGON-HF trial indicate that patients with HFpEF in North America are more obese

Table 1 Clinical characteristics of HFpEF patients by country

	Finland (n = 40)	Singapore (n = 20)	Sweden (n = 91)	United States (n = 51)	P-overall
Age (years)	75 (70;81)	74 (69;80)	78 (72;82)	69 (62;75)	<0.001
Sex (female)	24 (60)	8 (40)	43 (47)	36 (71)	0.024
HR (b.p.m)	72 (61;79)	66 (59;70)	67 (60;79)	69 (64;78)	0.498
SBP (mmHg)	139 (129;152)	161 (139;172)	140 (130;157)	126 (113;135)	<0.001
DBP (mmHg)	78 (73;88)	80 (71;93)	80 (70;85)	66 (59;75)	<0.001
BMI (kg/m ²)	29 (25;33)	26 (23;30)	27 (24;29)	32 (27;45)	<0.001
JVD	0 (0)	4 (20)	0 (0)	47 (92)	<0.001
Oedema	4 (10)	11 (55)	25 (28)	43 (84)	<0.001
Orthopnoea	0 (0)	9 (53)	7 (12)	29 (58)	<0.001
KCCQ	53 (44;68)	75 (58;86)	80 (58;88)	61 (39;78)	<0.001
6MWT (m)	400 (306;448)	265 (186;361)	331 (240;416)	345 (285;400)	0.038
RHI	0.69 (0.47;0.83)	1.77 (1.56;1.98)	1.85 (1.54;2.18)	1.29 (0.78;2.0)	<0.001
Ethnicity					<0.001
White	40 (100)	0 (0)	91 (100)	43 (84)	
Asian	0 (0)	20 (100)	0 (0)	1 (2)	
Black	0 (0)	0 (0)	0 (0)	7 (14)	
NYHA ^a					<0.001
I	0 (0)	0 (0)	3 (3)	0 (0)	
II	25 (63)	18 (90)	76 (84)	30 (59)	
III	15 (38)	1 (5)	12 (13)	21 (41)	
IV	0 (0)	1 (5)	0 (0)	0 (0)	
Co-morbidities					
AF	28 (70)	6 (30)	61 (67)	11 (22)	<0.001
Anaemia	8 (21)	8 (40)	34 (38)	25 (49)	0.052
CAD	3 (8)	7 (35)	24 (26)	5 (10)	0.007
CKD	28 (72)	5 (25)	49 (54)	23 (45)	0.004
DM	9 (23)	10 (50)	25 (28)	14 (28)	0.792
Hyperlipidaemia	19 (48)	17 (85)	45 (50)	30 (59)	0.022
Hypertension	35 (88)	20 (100)	72 (79)	43 (84)	0.120
Obesity	16 (40)	5 (25)	20 (22)	32 (63)	<0.001
Smoking	19 (48)	8 (40)	73 (80)	28 (55)	<0.001
Treatments					
ACE-inhibitor	11 (28)	10 (50)	36 (40)	8 (16)	0.008
ARB	18 (45)	8 (40)	41 (45)	18 (35)	0.689
Beta-blocker	37 (93)	16 (80)	70 (77)	26 (51)	<0.001
Diuretics	34 (85)	17 (85)	68 (75)	36 (71)	0.313
MRA	11 (28)	0 (0)	15 (17)	26 (51)	<0.001
Laboratory					
eGFR (mL/min/1.73 m ²)	54 (44;63)	73 (49;85)	58 (49;68)	62 (44;79)	0.032
Haemoglobin (g/L)	133 (123;146)	130 (115;142)	132 (121;140)	121 (112;131)	0.001
LDL (mmol/L)	2.0 (1.5;3.1)	2.4 (1.9;2.7)	2.4 (1.8;3.1)	1.9 (1.7;2.6)	0.133
NT-proBNP (pg/mL)	1220 (742;2040)	386 (130;1301)	1260 (812;1943)	198 (93;440)	<0.001
Troponin (ng/mL)	16 (10;28)	18 (14;25)	16 (11;25)	10 (10;10)	<0.001
Echocardiography					
LVEF (%)	58 (54;61)	64 (57;69)	58 (54;63)	64 (59;66)	<0.001
LAVI (mL/m ²)	40 (32;49)	36 (25;40)	41 (35;47)	29 (22;33)	<0.001
E/e'	13 (8.4;16)	13 (11;16)	12 (9;16)	12 (9.4;16)	0.570
LVMI (g/m ²)	105 (85.9;128)	111 (87.1;134)	111 (85;130)	94 (76;112)	0.112
Left atrial reservoir strain (%)	11 (9;20)	18 (12;25)	12 (8;18)	24 (16;28)	<0.001

Categorical variables are presented as number (n) and percentage (%) and continuous variables as median and upper and lower quartiles (Q1;Q3), P-value for overall comparisons.

6MWT, 6 minute walk test; ACE-inhibitor, angiotensin converting enzyme inhibitor; AF, atrial fibrillation/flutter; ARB, angiotensin receptor blocker; BMI, body mass index; CAD, coronary artery disease; CKD, chronic kidney disease; CMD, coronary microvascular dysfunction; DBP, diastolic blood pressure; E/e', early mitral diastolic velocity/early annular diastolic velocity; eGFR, estimated glomerular filtration (creatinine) rate; HR, heart rate; JVD, jugular vein distension; KCCQ, Kansas city cardiomyopathy questionnaire; LAVI, left atrial volume index; LDL, low density lipoprotein; LVEF, left ventricular ejection fraction; LVMI, left ventricular mass index; MRA, mineral corticoid receptor antagonist; NT-proBNP, N-terminal pro-brain natriuretic peptide; NYHA, New York Heart Association; RHI, reactive hyperemia index; SBP, systolic blood pressure.

^aNYHA class I on the day of enrolment into the study.

with diabetes mellitus (DM), whereas in Asia, they suffer from DM too, but obesity is less common, and in Europe, atrial fibrillation (AF) is more common.⁷ Prevalence and correlates of CMD in HFpEF (PROMIS-HFpEF) was a study with comprehensive characterization of HFpEF patients from North America, Asia, and Europe with the primary aim to study prevalence of CMD.²

Aims

In the present analysis, we explore the regional differences in CMD and clinical characteristics and the influence of region on the associations between clinical characteristics and CMD in patients from Finland, Singapore, Sweden, and United States.

Methods

Study design


We performed a retrospective analysis of patients enrolled in the prospective, multinational, multicentre, observational PROMIS-HFpEF study. Sites participated from four countries: Stockholm and Gothenburg (Sweden); Turku (Finland);

Chicago (United States); and Singapore. A thorough description of inclusion and exclusion criteria is available in supplementary materials of a previous publication.² In short, patients were required to have New York Heart Association II–IV, a left ventricular ejection fraction (LVEF) $\geq 40\%$, and one or more of the following: (i) prior hospitalization with evidence of left ventricular hypertrophy or left atrial dilatation; (ii) elevated natriuretic peptides; (iii) E/e' ratio ≥ 15 ; and (iv) elevated invasive capillary wedge pressures. Most important exclusion criteria were unknown unvascularized macrovascular coronary artery disease and a recorded LVEF ever $<40\%$. CMD was defined as coronary flow reserve <2.5 assessed by adenosine-induced versus basal coronary flow measured by transthoracic Doppler echocardiography, as previously described in PROMIS-HFpEF.²

Demographic, clinical, laboratory, echocardiographic, functional (6 min walk test; 6MWT), patient-reported quality of life data (Kansas City Cardiomyopathy Questionnaire; KCCQ) and peripheral endothelial dysfunction expressed as reactive hyperaemia index (RHI) measured through EndoPAT[®] were collected. Definitions are available in supplementary materials of a previous publication.²

All study participants provided written informed consent, and the institutional review board at each of the participating sites approved the study. The study complied with the Declaration of Helsinki.

Figure 1 Showing association between CMD and country. Prevalence of CMD presented as numbers and percentages n (%) for each country. Crude and adjusted odds ratios (OR) [95% confidence interval (CI)], for the associations between CMD and country. Point of reference USA at 1.0 (grey vertical line). Adjusted for age, sex, NT-proBNP, smoking, left atrial reservoir strain, and atrial fibrillation.



Statistical analysis

Descriptive data are presented as median and interquartile range (Q1:Q3) and numbers (*n*) and percentages (%). Comparisons between all countries were analysed using Kruskal–Wallis and Pearson's chi-square test as appropriate and presented as 'P-overall' (Table 1). To assess whether the regional prevalence of CMD differed based on differences in clinical characteristics, a logistic regression analysis was performed with CMD as the dependent variable adjusting for age, sex, N-terminal pro-brain natriuretic peptide (NT-proBNP), smoking, left atrial reservoir strain, and AF (Figure 1). The covariates were chosen from a univariable logistic regression analysis on CMD and baseline characteristics based on *P*-value <0.01 and if of clinical relevance. These univariable and multivariable analyses are presented as odds ratio, 95% confidence interval, and *P*-value and are available in Table S1.

The effect modification of country on the association between CMD and clinical characteristics was explored through a multivariable interaction analysis, adjusted with the same covariates above, presented as *P* for interaction (country*covariate) with CMD as the dependent variable. A *P*-value of <0.05 was set as significance level (Table 2). All analyses were performed using R 4.2.1.

Results

In total, 202 patients from Sweden (*n* = 91), United States (*n* = 51), Finland (*n* = 40), and Singapore (*n* = 20) had CMD assessed. Clinical characteristics are summarized in Table 1. Patients in the United States were the youngest (69 years) and in Sweden the oldest (78 years; *P*-overall <0.001). In Finland and Sweden, AF (70% and 67%) and CKD (72% and 54%) were common (*P*-overall < 0.001 and *P*-overall = 0.004). Obesity was present in the majority of the patients in the United States (63%; *P*-overall < 0.001). Both hyperlipidaemia (85%) and coronary artery disease (35%) were most prevalent in Singapore (*P*-overall = 0.022 and *P*-overall = 0.007). NT-proBNP levels were higher in Sweden (1260 pg/mL) and Finland (1220 pg/mL) compared with Singapore (386 pg/mL) and United States (198 pg/mL; *P*-overall < 0.001). Left atrial volume index was the lowest in the United States (29 mL/m²) and the highest in Sweden (41 mL/m²; *P*-overall<0.001). Finland displayed the lowest RHI and KCCQ (*P*-overall < 0.001 for both), and the highest 6MWT (*P*-overall = 0.038).

The prevalence of CMD varied and was the highest in Finland (88%) and the lowest in the United States (59%) (Figure 1). There was no difference in prevalence of CMD between countries after adjusting for age, sex, NT-proBNP, smoking, left atrial reservoir strain, and AF (Figure 1). There

Table 2 Interaction region on association between patient characteristics and CMD

Variables	<i>P</i> -value interaction (<i>n</i> = 202)
Age (years)	0.070
Sex (female)	0.688
SBP (mmHg)	0.445
DBP (mmHg)	0.979
BMI (kg/m ²)	0.664
JVD	0.835
Oedema	0.513
Co-morbidities	
AF	0.937
Anaemia	0.295
CAD	0.536
CKD	0.926
DM	0.886
Hyperlipidaemia	0.065
Hypertension	0.492
Obesity	0.928
Smoking	0.814
Treatments	
ACE-inhibitor	0.888
ARB	0.087
Beta-blocker	0.788
Diuretics	0.923
Laboratory	
eGFR (mL/min/1.73 m ²)	0.580
Haemoglobin (g/L)	0.288
LDL (mmol/L)	0.083
NT-proBNP (pg/mL)	0.679
Troponin (ng/mL)	0.143
Echocardiography	
LVEF (%)	0.507
LAVI (mL/m ²)	0.350
LVMI (g/m ²)	0.161
Left atrial strain (%)	0.426

P for interaction denotes *p*-value for effect modification by country.

ACE-inhibitor, angiotensin converting enzyme inhibitor; AF, atrial fibrillation/flutter; ARB, angiotensin receptor blocker; BMI, body mass index; CAD, coronary artery disease; CKD, chronic kidney disease; DBP, diastolic blood pressure; DM, diabetes mellitus; eGFR, estimated glomerular filtration (creatinine) rate; JVD, jugular vein distension; LAVI, left atrial volume index; LDL, low density lipoprotein; LVEF, left ventricular ejection fraction; LVMI, left ventricular mass index; NT-proBNP, N-terminal pro-brain natriuretic peptide; SBP, systolic blood pressure.

was no effect modification of country (interaction analysis) (Table 2).

Conclusions

CMD was common in all regions but varied in prevalence with differences in patient characteristics. Associations between clinical characteristics and CMD were similar across regions.

We confirm previous findings that regional phenotypes exist in HFpEF.⁷ In HFpEF patients, CMD was present in the majority regardless of country. Patients in Scandinavia were

older, with AF and impaired atrial function and high NT-proBNP that may contribute to a high prevalence of CMD.⁸ Peripheral endothelial dysfunction, expressed as a low RHI, was most common in Finland, possibly relating to CKD and CMD.⁹

The highest prevalence of CMD was in Finland and the lowest in the United States despite the more obese American HFpEF phenotype. Obesity is suggested as a driver of CMD and HFpEF¹ and the lower prevalence in the United States may be explained by younger age and lower prevalence of AF.⁸ Indeed, after adjusting for age, sex, NT-proBNP, smoking, left atrial reservoir strain, and AF, the prevalence of CMD was similar across regions. Patients in Singapore were hypertensive and, despite being leaner, had higher prevalence of DM, consistent with previous findings.⁷ Still, prevalence of CMD was high, possibly associated with a more perturbed metabolic phenotype with hyperlipidaemia and DM. The lack of effect modification of region for any of the associations between clinical characteristics and CMD suggests that potential 'drivers' of CMD are uniform across regions.

PROMIS-HFpEF was not designed primarily to investigate regional differences, which is reflected by the uneven population distribution across countries limited to patients from White and Asian populations represented. The LVEF cut-off was set at $\geq 40\%$, which includes patients with mildly reduced LVEF. However, only 20 patients (10%) displayed an LVEF $< 50\%$. Data on SGLT-2 inhibitors were not collected as they were not indicated for HF at the time.

CMD was present in the majority of patients with HFpEF, with the lowest prevalence in the United States. The association between countries and CMD disappeared after multivariable adjustment. Clinical characteristics associated with CMD were similar in all countries. CMD could be a therapeutic target for HFpEF regardless of regional phenotype.

Funding

PROMIS-HFpEF is an AstraZeneca sponsored study. Dr. Carolyn S. P. Lam is supported by a Clinician Scientist Award from the National Medical Research Council of Singapore. S. J. Shah is supported by research grants from the National Institutes of Health (U54 HL160273, R01 HL107577, R01 HL127028, R01 HL140731, and R01 HL149423), Actelion, AstraZeneca, Corvia, Novartis, and Pfizer. Dr. Lars H. Lund is supported by the Swedish Research Council (grants 2013-23897-104604-23 and 523-2014-2336) and the Swedish Heart Lung Foundation (grants 20120321 and 20150557). Dr. Jasper Tromp is supported by the National University of Singapore Start-up Grant, the Tier 1 Grant from the Ministry of Education, and the CS-IRG New Investigator Grant from the National Medical Research Council.

Acknowledgements

The following study staff are acknowledged for their work in the PROMIS-HFpEF study: Ann Lindström, Ann Hultman-Cadring, Neal Pohlman, Juliet Ryan, Tuija Vasankari, Miriam Kåveryd Holmström, and Sofie Andrén.

Conflict of interest

Dr. Faxén has received consulting fees from Orion Pharma and Anacardio. Dr. Sanjiv Shah has received consulting fees from Abbott, Actelion, AstraZeneca, Amgen, Aria CV, Axon Therapies, Bayer, Boehringer-Ingelheim, Boston Scientific, Bristol-Myers Squibb, Cardiora, Coridea, CVRx, Cycleron, Cytokinetics, Edwards Lifesciences, Eidos, Eisai, Imara, Impulse Dynamics, Intellia, Ionis, Ironwood, Lilly, Merck, MyoKardia, Novartis, Novo Nordisk, Pfizer, Prothena, Regeneron, Rivus, Sanofi, Shifamed, Tenax, Tenaya, and United Therapeutics. Dr. Carolyn S.P. Lam has received research support from Bayer and Roche Diagnostics; has served as consultant or on the Advisory Board/Steering Committee/Executive Committee for Abbott, Actelion, Alleviant Medical, Allysta Pharma, Amgen, AnaCardio AB, Applied Therapeutics, AstraZeneca, Bayer, Boehringer Ingelheim, Boston Scientific, Cytokinetics, Darma Inc., EchoNous Inc, Impulse Dynamics, Ionis Pharmaceutical, Janssen Research & Development LLC, Medscape/WebMD Global LLC, Merck, Novartis, Novo Nordisk, Prosciento Inc, Radcliffe Group Ltd., Roche Diagnostics, Sanofi, Siemens Healthcare Diagnostics and Us2.ai; and serves as co-founder & non-executive director of Us2.ai. Patent pending: PCT/SG2016/050217 Method for diagnosis and prognosis of chronic heart failure. US Patent No. 10,702,247. Automated clinical workflow that recognizes and analyses 2-dimensional and Doppler echo images for cardiac measurements and the diagnosis, prediction, and prognosis of heart disease. Dr. Antti Saraste has received research grants from Academy of Finland and Finnish Foundation for Cardiovascular Research during the conduct of the study; and consulting fees from GE healthcare, Novartis, Abbot, AstraZeneca. Dr. Camilla Hage has received consulting fees from Novartis, Roche Diagnostics and AnaCardio, research grants from Bayer and speaker and honoraria from MSD and Novartis. Supported by the Swedish Research Council [grant 20,180,899]. Dr. Lars H. Lund has received research grants from Novartis, Boehringer-Ingelheim, Vifor Pharma, AstraZeneca, Mundipharma and Relypsa and consulting fees from Novartis, Merck, Boehringer-Ingelheim, Sanofi, Bayer, Pharmacosmos, Myokardia, Medscape and AstraZeneca. Stock owner in Anacardio. Dr. Jasper Tromp has received consulting or speaker fees from Daiichi-Sankyo, Boehringer Ingelheim, Roche diagnostics and Us2.ai, owns patent

US-10702247-B2 unrelated to the present work. All other authors have no disclosures to report.

Table S1. Associations between patient characteristics and coronary microvascular dysfunction.

Supporting information

Additional supporting information may be found online in the Supporting Information section at the end of the article.

References

- Paulus WJ, Tschope C. A novel paradigm for heart failure with preserved ejection fraction: Comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation. *J Am Coll Cardiol* 2013;**62**: 263–271. doi:10.1016/j.jacc.2013.02.092
- Shah SJ, Lam CSP, Svedlund S, Saraste A, Hage C, Tan RS, *et al.* Prevalence and correlates of coronary microvascular dysfunction in heart failure with preserved ejection fraction: PROMIS-HFpEF. *Eur Heart J* 2018;**39**:3439–3450. doi:10.1093/eurheartj/ehy531
- Hage C, Svedlund S, Saraste A, Faxen UL, Benson L, Fermer ML, *et al.* Association of coronary microvascular dysfunction with heart failure hospitalizations and mortality in heart failure with preserved ejection fraction: A follow-up in the PROMIS-HFpEF study. *J Card Fail* 2020;**26**:1016–1021. doi:10.1016/j.cardfail.2020.08.010
- Solomon SD, McMurray JJV, Claggett B, de Boer RA, DeMets D, Hernandez AF, *et al.* Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction. *N Engl J Med* 2022;**387**:1089–1098. doi:10.1056/NEJMoa2206286
- Anker SD, Butler J, Filippatos G, Ferreira JP, Bocchi E, Bohm M, *et al.* Empagliflozin in heart failure with a preserved ejection fraction. *N Engl J Med* 2021;**385**: 1451–1461. doi:10.1056/NEJMoa2107038
- Shah SJ, Katz DH, Selvaraj S, Burke MA, Yancy CW, Gheorghiadu M, *et al.* Phenomapping for novel classification of heart failure with preserved ejection fraction. *Circulation* 2015;**131**:269–279. doi:10.1161/CIRCULATIONAHA.114.010637
- Tromp J, Claggett BL, Liu J, Jackson AM, Jhund PS, Kober L, *et al.* Global differences in heart failure with preserved ejection fraction: The PARAGON-HF trial. *Circ Heart Fail* 2021;**14**:e007901. doi:10.1161/CIRCHEARTFAILURE.120.007901
- Ozcan C, Allan T, Besser SA, de la Pena A, Blair J. The relationship between coronary microvascular dysfunction, atrial fibrillation and heart failure with preserved ejection fraction. *Am J Cardiovasc Dis* 2021;**11**:29–38.
- Hirata Y, Sugiyama S, Yamamoto E, Matsuzawa Y, Akiyama E, Kusaka H, *et al.* Endothelial function and cardiovascular events in chronic kidney disease. *Int J Cardiol* 2014;**173**:481–486. doi:10.1016/j.ijcard.2014.03.085